Year None 2026 2025 2024 2023 2022 2021 2020 2019 Nov 06, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nov 05, 2026 Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Se Nov 04, 2026 Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update Oct 28, 2026 Arcutis Appoints Rob Scott, MD to Board of Directors Oct 27, 2026 Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference Oct 21, 2026 Arcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026 Oct 09, 2026 Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV a Oct 06, 2026 Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award Oct 02, 2026 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Current page 1 Page 2 Page 3 Page 4 Page 5 Next page next › Last page last » Displaying 1 - 9 of 43